Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARγ agonist

Biochemical Journal

Volumn 438, Issue 1, 2011, Pages 111-119

  Goto, Tsuyoshi ^a   Nagai, Hiroyuki ^a   Egawa, Kahori ^a   Kim, Young Il ^a   Kato, Sota ^a   Taimatsu, Aki ^a   Sakamoto, Tomoya ^a   Ebisu, Shogo ^b   Hohsaka, Takahiro ^c   Miyagawa, Hiroh ^d   Murakami, Shigeru ^d   Takahashi, Nobuyuki ^a   Kawada, Teruo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Protein Express Company Limited   (Japan)

^c JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

^d TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Adipocyte differentiation; Farnesyl pyrophosphate (FPP); Ligand; Metabolic syndrome; Mevalonate metabolite; Peroxisome proliferator activated receptor (PPAR )

Indexed keywords

FARNESYL DIPHOSPHATE; GLUTATHIONE TRANSFERASE; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROID RECEPTOR COACTIVATOR 1; ZARAGOZIC ACID A;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; IN VITRO STUDY; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BINDING; TRANSCRIPTION REGULATION;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; LUCIFERASES; MEVALONIC ACID; MICE; NUCLEAR RECEPTOR COACTIVATOR 1; POLYISOPRENYL PHOSPHATES; PPAR GAMMA; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SESQUITERPENES;

EID: 79960823883     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20101939     Document Type: Article

References (65)

1. Kadowaki, T., Yamauchi, T., Kubota, N., Hara, K., Ueki, K. and Tobe, K. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116, 1784-1792
2. Matsuzawa, Y. (2006) The metabolic syndrome and adipocytokines. FEBS Lett. 580, 2917-2921
3. Sakai, T., Sakaue, H., Nakamura, T., Okada, M., Matsuki, Y., Watanabe, E., Hiramatsu, R., Nakayama, K., Nakayama, K. I. and Kasuga, M. (2007) Skp2 controls adipocyte proliferation during the development of obesity. J. Biol. Chem. 282, 2038-2046
4. Spiegelman, B. M. and Flier, J. S. (1996) Adipogenesis and obesity: rounding out the big picture. Cell 87, 377-389 (Pubitemid 26374313)
5. Glass, C. K. (2006) Going nuclear in metabolic and cardiovascular disease. J. Clin. Invest. 116, 556-560
6. Yamauchi, T., Kamon, J., Waki, H., Murakami, K., Motojima, K., Komeda, K., Ide, T., Kubota, N., Terauchi, Y., Tobe, K. et al. (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276, 41245-41254
7. Bell-Parikh, L. C., Ide, T., Lawson, J. A., McNamara, P., Reilly, M. and FitzGerald, G. A. (2003) Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J. Clin. Invest. 112, 945-955
8. Rosen, E. D. and Spiegelman, B. M. (2001) PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276, 37731-37734
9. Tzameli, I., Fang, H., Ollero, M., Shi, H., Hamm, J. K., Kievit, P., Hollenberg, A. N. and Flier, J. S. (2004) Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J. Biol. Chem. 279, 36093-36102
10. Edwards, P. A. and Ericsson, J. (1999) Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu. Rev. Biochem. 68, 157-185
11. Martin, G., Duez, H., Blanquart, C., Berezowski, V., Poulain, P., Fruchart, J. C., Najib-Fruchart, J., Glineur, C. and Staels, B. (2001) Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J. Clin. Invest. 107, 1423-1432
12. Forman, B. M., Ruan, B., Chen, J., Schroepfer, Jr, G. J. and Evans, R. M. (1997) The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc. Natl. Acad. Sci. U.S.A. 94, 10588-10593
13. Argmann, C. A., Edwards, J. Y., Sawyez, C. G., O'Neil, C. H., Hegele, R. A., Pickering, J. G. and Huff, M. W. (2005) Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J. Biol. Chem. 280, 22212-22221
14. Yano, M., Matsumura, T., Senokuchi, T., Ishii, N., Murata, Y., Taketa, K., Motoshima, H., Taguchi, T., Sonoda, K., Kukidome, D. et al. (2007) Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ. Res. 100, 1442-1451
15. Takahashi, N., Kawada, T., Goto, T., Yamamoto, T., Taimatsu, A., Matsui, N., Kimura, K., Saito, M., Hosokawa, M., Miyashita, K. et al. (2002) Dual action of isoprenols from herbal medicines on both PPARgamma and PPARalpha in 3T3-L1 adipocytes and HepG2 hepatocytes. FEBS Lett. 514, 315-322 (Pubitemid 34273961)
16. Goto, T., Takahashi, N., Kato, S., Egawa, K., Ebisu, S., Moriyama, T., Fushiki, T. and Kawada, T. (2005) Phytol directly activates peroxisome proliferator-activated receptor alpha (PPARalpha) and regulates gene expression involved in lipid metabolism in PPARalpha-expressing HepG2 hepatocytes. Biochem. Biophys. Res. Commun. 337, 440-445
17. Kuroyanagi, K., Kang, M. S., Goto, T., Hirai, S., Ohyama, K., Kusudo, T., Yu, R., Yano, M., Sasaki, T., Takahashi, N. et al. (2008) Citrus auraptene acts as an agonist for PPARs and enhances adiponectin production and MCP-1 reduction in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 366, 219-225
18. Takahashi, N., Kawada, T., Goto, T., Kim, C. S., Taimatsu, A., Egawa, K., Yamamoto, T., Jisaka, M., Nishimura, K., Yokota, K. et al. (2003) Abietic acid activates peroxisome proliferator-activated receptor-gamma (PPARgamma) in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism. FEBS Lett. 550, 190-194 (Pubitemid 37281380)
19. Park, J. Y., Kawada, T., Han, I. S., Kim, B. S., Goto, T., Takahashi, N., Fushiki, T., Kurata, T. and Yu, R. (2004) Capsaicin inhibits the production of tumor necrosis factor alpha by LPS-stimulated murine macrophages, RAW 264.7: a PPARgamma ligand-like action as a novel mechanism. FEBS Lett. 572, 266-270
20. Takahashi, N., Kawada, T., Yamamoto, T., Goto, T., Taimatsu, A., Aoki, N., Kawasaki, H., Taira, K., Yokoyama, K. K., Kamei, Y. et al. (2002) Overexpression and ribozyme-mediated targeting of transcriptional coactivators CREB-binding protein and p300 revealed their indispensable roles in adipocyte differentiation through the regulation of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 277, 16906-16912
21. Abe, R., Shiraga, K., Ebisu, S., Takagi, H. and Hohsaka, T. (2010) Incorporation of fluorescent non-natural amino acids into N-terminal tag of proteins in cell-free translation and its dependence on position and neighboring codons. J. Biosci. Bioeng. 110, 32-38
22. Nagai, H., Ebisu, S., Abe, R., Goto, T., Takahashi, N., Hosaka, T. and Kawada, T. (2011) Development of a novel PPARγ ligand screening system using pinpoint fluorescence-probed protein. Biosci. Biotechnol. Biochem. 75, 337-341
23. Case, D. A., Darden, T. A., Cheatham, III, T. E., Simmerling, C. L., Wang, J., Duke, R. E., Luo, R., Merz, K. M., Pearlman, D. A., Crowley, M. et al. (2006) AMBER 9 Users' Manual, University of California, San Francisco, CA
24. Fujitani, H., Tanida, Y. and Matsuura, A. (2009) Massively parallel computation of absolute binding free energy with well-equilibrated states. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 79, 021914
25. Wang, J., Wolf, R. M., Caldwell, J. W., Kollamn, P. A. and Case, D. A. (2004) Development and testing of a general Amber force field. J. Comput. Chem. 25, 1157-1174
26. Jorgensen, W. L., Chandrasekhar, J., Madura, J. and Klein, M. L. (1983) Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926-935
27. Jakalian, A., Bush, B. L., Jack, D. B. and Bayly, C. I. (2000) Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I. Method. J. Comput. Chem. 21, 132-146
28. Jakalian, A., Jack, D. B. and Bayly, C. I. (2002) Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J. Comput. Chem. 23, 1623-1641
29. Tong, H., Holstein, S. A. and Hohl, R. J. (2005) Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Anal. Biochem. 336, 51-59
30. Leibowitz, M. D., Ardecky, R. J., Boehm, M. F., Broderick, C. L., Carfagna, M. A., Crombie, D. L., D'Arrigo, J., Etgen, G. J., Faul, M. M., Grese, T. A. et al. (2006) Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes. Endocrinology 147, 1044-1053 (Pubitemid 43113025)
31. DiRenzo, J., Söderstrom, M., Kurokawa, R., Ogliastro, M. H., Ricote, M., Ingrey, S., Hörlein, A., Rosenfeld, M. G. and Glass, C. K. (1997) Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol. Cell. Biol. 17, 2166-2176
32. Gelman, L., Zhou, G., Fajas, L., Raspé, E., Fruchart, J. C. and Auwerx, J. (1999) p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. J. Biol. Chem. 274, 7681-7688
33. Armoni, M., Kritz, N., Harel, C., Bar-Yoseph, F., Chen, H., Quon, M. J. and Karnieli, E. (2003) Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. J. Biol. Chem. 278, 30614-30623
34. Tontonoz, P., Hu, E. and Spiegelman, B. M. (1994) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79, 1147-1156
35. Houten, S. M., Frenkel, J. and Waterham, H. R. (2003) Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell. Mol. Life Sci. 60, 1118-1134
36. Zhang, F. L. and Casey, P. J. (1996) Protein prenylation: molecular mechanisms and functional consequencesProtein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241-269
37. Bar-Sagi, D. and Hall, A. (2000) Ras and Rho GTPases: a family reunion. Cell 103, 227-238
38. Klemm, D. J., Leitner, J. W., Watson, P., Nesterova, A., Reusch, J. E., Goalstone, M. L. and Draznin, B. (2001) Insulin-induced adipocyte differentiation. Activation of CREB rescues adipogenesis from the arrest caused by inhibition of prenylation. J. Biol. Chem. 276, 28430-28435
39. Gibbs, J. B., Pompliano, D.L, Mosser, S. D., Rands, E., Lingham, R. B., Singh, S. B., Scolnick, E. M., Kohl, N. E. and Oliff, A. (1993) Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J. Biol. Chem. 268, 7617-7620
40. Oh, D. Y., Yoon, J. M., Moon, M. J., Hwang, J. I., Choe, H., Lee, J. Y., Kim, J. I., Kim, S., Rhim, H., O'Dell, D. K. et al. (2006) Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J. Biol. Chem. 283, 21054-21064
41. Murthy, S., Tong, H. and Hohl, R. J. (2005) Regulation of fatty acid synthesis by farnesyl pyrophosphate. J. Biol. Chem. 280, 41793-41804
42. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M. and Kliewer, S. A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270, 12953-12956
43. Ferry, G., Bruneau, V., Beauverger, P., Goussard, M., Rodriguez, M., Lamamy, V., Dromaint, S., Canet, E., Galizzi, J. P. and Boutin, J. A. (2001) Binding of prostaglandins to human PPARgamma: tool assessment and new natural ligands. Eur. J. Pharmacol. 417, 77-89
44. Murakami, K., Ide, T., Nakazawa, T., Okazaki, T., Mochizuki, T. and Kadowaki, T. (2001) Fatty-acyl-CoA thioesters inhibit recruitment of steroid receptor co-activator 1 to a and c isoforms of peroxisome-proliferator-activated receptors by competing with agonists. Biochem. J. 353, 231-238 (Pubitemid 32096930)
45. Rocchi, S., Picard, F., Vamecq, J., Gelman, L., Potier, N., Zeyer, D., Dubuquoy, L., Bac, P., Champy, M. F., Plunket, K. D. et al. (2001) A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell 8, 737-747 (Pubitemid 33030208)
46. Kodera, Y., Takeyama, K., Murayama, A., Suzawa, M., Masuhiro, Y. and Kato, S. (2000) Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J. Biol. Chem. 275, 33201-33204
47. Camp, H. S., Li, O., Wise, S. C., Hong, Y. H., Frankowski, C. L., Shen, X., Vanbogelen, R. and Leff, T. (2000) Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 49, 539-547 (Pubitemid 30183741)
48. Risérus, U., Tan, G. D., Fielding, B. A., Neville, M. J., Currie, J., Savage, D. B., Chatterjee, V. K., Frayn, K. N., O'Rahilly, S. and Karpe, F. (2005) Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma. Diabetes 54, 1379-1384 (Pubitemid 40586667)
49. Kurebayashi, S., Hirose, T., Miyashita, Y., Kasayama, S. and Kishimoto, T. (1997) Thiazolidinediones downregulate stearoyl-CoA desaturase 1 gene expression in 3T3-L1 adipocytes. Diabetes 46, 2115-2118 (Pubitemid 27512107)
50. Nicholson, A. C., Hajjar, D. P., Zhou, X., He, W., Gotto, Jr, A. M. and Han, J. (2007) Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPARgamma and Pref-1 expression. Br. J. Pharmacol. 151, 807-815
51. Goldstein, J. L. and Brown, M. S. (1990) Regulation of the mevalonate pathway. Nature 343, 425-430
52. Sakakura, Y., Shimano, H., Sone, H., Takahashi, A., Inoue, N., Toyoshima, H., Suzuki, S. and Yamada, N. (2001) Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis. Biochem. Biophys. Res. Commun. 286, 176-183
53. Boizard, M., Le Liepvre, X., Lemarchand, P., Foufelle, F., Ferré, P. and Dugail, I. (1998) Obesity-related overexpression of fatty-acid synthase gene in adipose tissue involves sterol regulatory element-binding protein transcription factors. J. Biol. Chem. 273, 29164-29171
54. Le Lay, S, Ferré, P. and Dugail, I. (2004) Adipocyte cholesterol balance in obesity. Biochem. Soc. Trans. 32, 103-106
55. Kim, J. B. and Spiegelman, B. M. (1996) ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 10, 1096-1107
56. Kim, J. B., Wright, H. M., Wright, M. and Spiegelman, B. M. (1998) ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc. Natl. Acad. Sci. U.S.A. 95, 4333-4337
57. Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H. et al. (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103, 357-362
58. Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A. and McInnes, G. T. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149-1158
59. Diabetes Atorvastin Lipid Intervention (DALI) Study Group (2001) The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24, 1335-1341
60. Nakata, M., Nagasaka, S., Kusaka, I., Matsuoka, H., Ishibashi, S. and Yada, T. (2006) Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 49, 1881-1892 (Pubitemid 44025043)
61. Altshuler, D., Hirschhorn, J. N., Klannemark, M., Lindgren, C. M., Vohl, M. C., Nemesh, J., Lane, C. R., Schaffner, S. F., Bolk, S., Brewer, C. et al. (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26, 76-80
62. Yamauchi, T., Waki, H., Kamon, J., Murakami, K., Motojima, K., Komeda, K., Miki, H., Kubota, N., Terauchi, Y., Tsuchida, A. et al. (2001) Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J. Clin. Invest. 108, 1001-1013
63. Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T. et al. (1999) PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4, 597-609 (Pubitemid 29531139)
64. Miles, P. D., Barak, Y., He, W., Evans, R. M. and Olefsky, J. M. (2000) Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest. 105, 287-292
65. Saisho, Y., Morimoto, A. and Umeda, T. (1997) Determination ofFPP in dog and human plasma by high-performance liquid chromatography with fluorescence detection. Anal. Biochem. 252, 89-95